241.43
前日終値:
$238.76
開ける:
$238.2
24時間の取引高:
171.47K
Relative Volume:
0.34
時価総額:
$311.50B
収益:
$3.81B
当期純損益:
$-644.79M
株価収益率:
-38.69
EPS:
-6.24
ネットキャッシュフロー:
$-669.77M
1週間 パフォーマンス:
+5.71%
1か月 パフォーマンス:
-3.09%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
Beigene Ltd Adr Stock (ONC) Company Profile
名前
Beigene Ltd Adr
セクター
電話
13459494123
住所
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-07 | 開始されました | RBC Capital Mkts | Outperform |
2025-03-03 | アップグレード | BofA Securities | Neutral → Buy |
2024-12-03 | 再開されました | Morgan Stanley | Overweight |
2024-09-18 | 開始されました | JMP Securities | Mkt Outperform |
2024-02-06 | 再開されました | JP Morgan | Overweight |
2023-09-12 | 開始されました | Macquarie | Outperform |
2023-08-17 | 開始されました | Jefferies | Buy |
2023-07-17 | 開始されました | Citigroup | Buy |
2023-06-30 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2023-01-12 | 開始されました | Daiwa Securities | Buy |
2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
2022-10-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2022-08-09 | 再開されました | JP Morgan | Overweight |
2022-03-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2022-02-07 | 開始されました | Deutsche Bank | Buy |
2021-10-12 | 開始されました | Bernstein | Outperform |
2021-10-06 | アップグレード | CLSA | Underperform → Buy |
2021-03-08 | 開始されました | China Renaissance | Buy |
2021-03-01 | ダウングレード | CLSA | Outperform → Underperform |
2020-11-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
2020-11-06 | ダウングレード | Maxim Group | Buy → Hold |
2020-11-06 | ダウングレード | Piper Sandler | Neutral → Underweight |
すべてを表示
Beigene Ltd Adr (ONC) 最新ニュース
BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India
Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX
BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins patent challenge against Pharmacyclics - Investing.com
BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
Beigene Ltd Adr (ONC) 財務データ
収益
当期純利益
現金流量
EPS
Beigene Ltd Adr (ONC) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Wang Xiaodong | Chair, Scientific Advisory Brd |
May 13 '25 |
Sale |
223.50 |
41,760 |
9,333,272 |
0 |
OYLER JOHN | Chief Executive Officer |
May 09 '25 |
Option Exercise |
0.50 |
4,055,415 |
2,027,708 |
10,154,040 |
Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Option Exercise |
6.50 |
41,760 |
271,440 |
41,760 |
Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Sale |
242.66 |
41,760 |
10,133,595 |
0 |
大文字化:
|
ボリューム (24 時間):